856. Treatment-Resistant Schizophrenia: Definitions, Current Pharmacological Strategies, and Emerging Pipeline Therapies
Abstract Background Antipsychotic monotherapy is the guideline-supported mainstay of treatment for schizophrenia. However, approximately 40% of patients fail to achieve an adequate response in randomized controlled trials, highlighting the significant clinical challenge of treatment-resistant schizophrenia (TRS). Despi...